http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H07291869-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0931241d9441d023245580a92141bf68 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-66 |
| filingDate | 1994-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fd7156027675c5f0c495b9dc84a49d4a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5fcd1deb6bcad3722a147a274d50466 |
| publicationDate | 1995-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-H07291869-A |
| titleOfInvention | Preparation for oral administration |
| abstract | (57) [Summary] The present invention has the general formula ## STR1 ## which is represented by, for example, diethyl 4-[(4-bromo-2-cyanophenyl) carbamoyl] benzylphosphonate. [In the formula, R represents a lower alkyl group and X represents a halogen atom. ] A pharmaceutical preparation for oral administration containing an ultrafine powder of a phosphonic acid diester derivative represented by the following as an active ingredient. [Effect] The drug product of the present invention has stable and high bioavailability for effectively exerting the drug effect of the phosphonic acid diester derivative, and thus has excellent properties as a drug product for treating hyperlipidemia. I have. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2004161653-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0057881-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-4494712-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7144585-B1 |
| priorityDate | 1994-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 27.